Krompecher E. Apocrine carcinoma of the breast. Beitr Path Anat. 1916;62:403.

Google Scholar 

Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer. 1968;21(4):756–63.

Article  CAS  PubMed  Google Scholar 

Tan PH, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181–5.

Article  PubMed  Google Scholar 

Mills AM, Gottlieb EC, Wendroth MS, Brenin MC, Atkins KA. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers. Am J Surg Pathol. 2016;40(8):1109–16. https://doi.org/10.1097/PAS.0000000000000671.

Article  PubMed  Google Scholar 

Liu X, Feng C, Liu J, et al. The importance of EGFR as a biomarker in molecular apocrine breast cancer. Hum Pathol. 2018;77:1–10. https://doi.org/10.1016/j.humpath.2018.01.016.

Article  CAS  PubMed  Google Scholar 

Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, Gatalica Z. Apocrine carcinoma of the breast: A comprehensive review. Histol Histopathol. 2013;28:1393–409.

PubMed  Google Scholar 

Nozaki F, Hirotani Y, Nakanishi Y, et al. p62 Regulates the Proliferation of Molecular Apocrine Breast Cancer Cells. Acta Histochem Cytochem. 2016;49(4):125–30. https://doi.org/10.1267/ahc.16013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saridakis A, Berger ER, Harigopal M, et al. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Ann Surg Oncol. 2021;28(10):5610–6. https://doi.org/10.1245/s10434-021-10518-9.

Article  PubMed  Google Scholar 

Arciero CA, Diehl AH III, Liu Y, Sun Q, Gillespie T, Li X, Subhedar P. Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers. J Surg Oncol. 2020Nov;122(6):1232–9.

Article  PubMed  PubMed Central  Google Scholar 

Mills MN, Yang GQ, Oliver DE, et al. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur J Cancer. 2018;98:48–58. https://doi.org/10.1016/j.ejca.2018.04.011.

Article  PubMed  Google Scholar 

Montagna E, Cancello G, Pagan E, et al. Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. Breast. 2020;53:138–42. https://doi.org/10.1016/j.breast.2020.07.003.

Article  PubMed  PubMed Central  Google Scholar 

Xu Y, Zhang W, He J, et al. Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis. Breast. 2022;66:8–14. https://doi.org/10.1016/j.breast.2022.08.011.

Article  PubMed  PubMed Central  Google Scholar 

Liu X, Feng C, Liu J, et al. Androgen receptor and heat shock protein 27 co-regulate the malignant potential of molecular apocrine breast cancer. J Exp Clin Cancer Res. 2018;37(1):90. https://doi.org/10.1186/s13046-018-0762-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Högel B, Mehta K, Kaltenecker G, Rüdiger T, Pfitzner B, Kittel K, Fiedler B, Baumann K, Moll R, Dietel M, Eidtmann H, Thomssen C, Loibl S. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 2014;14:546. https://doi.org/10.1186/1471-2407-14-546.

Article  PubMed  PubMed Central  Google Scholar 

Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977Oct;40(4):1365–85.

Article  CAS  PubMed  Google Scholar 

Quinn, C., D’Arcy, C. (2018). Invasive Carcinoma with Medullary Features. In: van Krieken, J. (eds) Encyclopedia of Pathology. Encyclopedia of Pathology. Springer, Cham. https://doi.org/10.1007/978-3-319-28845-1_4714-2

Gaffey MJ, Mills SE, Frierson HF Jr, Zarbo RJ, Boyd JC, Simpson JF, Weiss LM. Medullary carcinoma of the breast interobserver variability in histopathologic diagnosis. Modern Pathol: Official J United States Canadian Academy Pathol, Inc. 1995;8(1):31–8.

CAS  Google Scholar 

Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Öhlschlegel C, Price KN, Gelber RD, Regan MM, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Annals Oncol : Official J Eur Soc Med Oncol. 2012;23(11):2843–51. https://doi.org/10.1093/annonc/mds105.

Article  CAS  Google Scholar 

Jacquemier, J., Padovani, L., Rabayrol, L., Lakhani, S. R., Penault-Llorca, F., Denoux, Y., Fiche, M., Figueiro, P., Maisongrosse, V., Ledoussal, V., Martinez Penuela, J., Udvarhely, N., El Makdissi, G., Ginestier, C., Geneix, J., Charafe-Jauffret, E., Xerri, L., Eisinger, F., Birnbaum, D., Sobol, H., … Breast Cancer Linkage Consortium. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005;207(3):260–8. https://doi.org/10.1002/path.1845.

Article  CAS  Google Scholar 

Martinez SR, Beal SH, Canter RJ, Chen SL, Khatri VP, Bold RJ. Medullary carcinoma of the breast: a population-based perspective. Med Oncol (Northwood, London, England). 2011;28(3):738–44. https://doi.org/10.1007/s12032-010-9526-z.

Article  PubMed Central  Google Scholar 

Cao AY, He M, Huang L, Shao ZM, Di GH. Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified. World J Surg Oncol. 2013;11:91. https://doi.org/10.1186/1477-7819-11-91.

Article  PubMed  PubMed Central  Google Scholar 

Vu-Nishino H, Tavassoli FA, Ahrens WA, Haffty BG. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiation Oncol Biol Phys. 2005;15;62(4):1040–7.

Article  Google Scholar 

Kouhen F, Benhmidou N, Afif M, Rais F, Khamou M, Khanoussi B, El Menaoui O, Elkacemi H, Elmajjaoui S, Kebdani T, Benjaafar N. Prognosis of Medullary Carcinoma of the Breast: 10 years’ Experience in a Single Institution. Breast J. 2017;23(1):112–4. https://doi.org/10.1111/tbj.12699.

Article  PubMed  Google Scholar 

Thurman SA, Schnitt SJ, Connolly JL, Gelman R, Silver B, Harris JR, Recht A. Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys. 2004;59(1):152–9. https://doi.org/10.1016/j.ijrobp.2003.10.029.

Article  PubMed  Google Scholar 

Mateo AM, Pezzi TA, Sundermeyer M, Kelley CA, Klimberg VS, Pezzi CM. Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data Base. J Surg Oncol. 2016;114(5):533–6. https://doi.org/10.1002/jso.24367.

Article  CAS  PubMed  Google Scholar 

•• Elimimian EB, Samuel TA, Liang H, Elson L, Bilani N, Nahleh ZA. Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US. JAMA Netw Open. 2021;4(4):e214123. Published 2021 Apr 1. https://doi.org/10.1001/jamanetworkopen.2021.4123. This paper explores the heterogeneity of triple negative breast cancers by evaluating rare subtypes medullary carcinoma, adenoid cystic carcinoma, and metaplastic breast carcinoma. Its findings suggest that medullary carcinomas were most common, but metaplastic had the worst overall 5-year survival.

Wang XX, Jiang YZ, Liu XY, Li JJ, Song CG, Shao ZM. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database. Oncotarget. 2016;7(16):22665–73. https://doi.org/10.18632/oncotarget.8142.

Article  PubMed  PubMed Central  Google Scholar 

Chen H, Pu S, Wang L, et al. A risk stratification model to predict chemotherapy benefit in medullary carcinoma of the breast: a population-based SEER database. Sci Rep. 2023;13(1):10704. https://doi.org/10.1038/s41598-023-37915-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marchiò C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or “The strange case of Dr Jekyll and Mr Hyde” of exocrine gland carcinomas). J Clin Pathol. 2010;63(3):220–8. https://doi.org/10.1136/jcp.2009.073908.

Article  PubMed  Google Scholar 

Miyai K, Schwartz MR, Divatia MK, Anton RC, Park YW, Ayala AG, et al. Adenoid cystic carcinoma of breast: Recent advances. World J Clin Cases. 2014;2(12):732–41. https://doi.org/10.12998/wjcc.v2.i12.732.

Article  PubMed  PubMed Central  Google Scholar 

Foschini MP, Morandi L, Asioli S, Giove G, Corradini AG, Eusebi V. The morphological spectrum of salivary gland type tumours of the breast. Pathology. 2017;49(2):215–27. https://doi.org/10.1016/j.pathol.2016.10.011.

Article  PubMed  Google Scholar 

Kim J, Geyer FC, Martelotto LG, Ng CK, Lim RS, Selenica P, Li A, Pareja F, Fusco N, Edelweiss M, Kumar R. MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB–NFIB fusion gene. J Pathol. 2018;244(2):143–50.

Article  PubMed  Google Scholar 

Li L, Zhang D, Ma F. Adenoid cystic carcinoma of the breast may be exempt from adjuvant chemotherapy. J Clin Med. 2022;11(15):4477.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldbach MM, Hoffman DI, Burkbauer L, Nayak A, Tchou J. Treatment Patterns and Clinical Outcomes of Adenoid Cystic Breast Carcinoma: A Single-Institution Experience. Am Surg. 2020;86(12):1684–90. https://doi.org/10.1177/0003134820942287.

Article  PubMed  Google Scholar 

Romeira D, Cardoso D, Miranda H, Martins A. Adenoid cystic carcinoma: triple negative breast cancer with good prognosis. BMJ Case Rep. 2016;2016:bcr2015213704. https://doi.org/10.1136/bcr-2015-213704.

Article  PubMed  PubMed Central  Google Scholar 

Thompson K, Grabowski J, Saltzstein SL, Sadler GR, Blair SL. Adenoid cystic breast carcinoma: is axillary staging necessary in all cases? Results from the California Cancer Registry. Breast J. 2011;17(5):485–9. https://doi.org/10.1111/j.1524-4741.2011.01117.x.

Article  PubMed